Section 5 of 6
Economic information and modeling report
5 evidence topics · 4 sources
Modeling overview
Summary: published economic evaluations, HTA status, and commercial forecasts
No published cost-effectiveness analysis, budget impact model, or health technology assessment of inaxaplin or of any other APOL1-targeted therapy was identified, and no ICER review was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. The only APOL1-related economic analysis identified is a “crude cost analysis” of donor genotyping at one center, in which 1 of 26 potential African American living donors had a high-risk genotype. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Guggenheim Securities analysts assigned a 65% probability of success in primary AMKD and 45% in the type 2 diabetes population; Vertex investor relations stated that AMPLITUDE could address about 150,000 people in the U.S. and Europe ; Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000.
Published cost-effectiveness analyses, budget impact models, and HTA reviews of inaxaplin
No evidence found.
Cost-effectiveness of emerging APOL1-targeted therapies
“At present, the cost-effectiveness of the aforementioned emerging therapeutic strategies remains uncertain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If similar pricing were applied to therapies for APOL1-mediated kidney disease, such intervention would be unaffordable in sub-Saharan Africa, the region bearing the highest disease burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost analysis of APOL1 genotyping of potential living kidney donors
Revenue forecast for inaxaplin in the United States
Analyst probability of success and company estimates of the addressable population
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.